BRIUMVI Dosing Simplified: TG Therapeutics' Phase 3 Trial Meets Primary Endpoint
TGTX sits 62% above its 52-week low of $25.28.
Summary
TG Therapeutics announced positive topline results from its Phase 3 ENHANCE trial for BRIUMVI, its approved multiple sclerosis drug. The trial met its primary endpoint, demonstrating that a single Day 1 infusion is bioequivalent to the current two-infusion initiation regimen. This streamlined dosing simplifies treatment, potentially accelerating patient access and reducing burdens on infusion centers, which could enhance BRIUMVI's market adoption. The company plans to submit a supplemental Biologics License Application (BLA) in the second half of 2026. This follows a series of positive developments for BRIUMVI, including increased revenue guidance and completion of enrollment for a subcutaneous formulation trial.
At the time of this announcement, TGTX was trading at $41.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $25.28 to $44.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.